[Skip to Content]
[Skip to Content Landing]
Viewpoint
February 1, 2012

The Ethical Hazards and Programmatic Challenges of Genomic Newborn Screening

Author Affiliations

Author Affiliations: Department of Bioethics (Dr Goldenberg) and Center for Genetic Research Ethics and Law (Drs Goldenberg and Sharp), Case Western Reserve University School of Medicine, Cleveland, Ohio; and Department of Bioethics, Center for Ethics, Humanities and Spiritual Care, and Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio (Dr Sharp).

JAMA. 2012;307(5):461-462. doi:10.1001/jama.2012.68

Advances in next-generation sequencing technologies have the potential to spur better integration of genetic testing into patient care. Appropriate utilization of these technologies will require the capacity to manage, interpret, and communicate large amounts of personal genetic information.1 Because the clinical infrastructure necessary to support these activities is currently limited,2 it is likely that the earliest applications of whole-genome sequencing will be restricted to settings in which genetic testing is already a routine part of clinical or public health practice, such as state newborn screening (NBS) programs.

First Page Preview View Large
First page PDF preview
First page PDF preview
×